Dentsply International (XRAY) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.57%. A quarter ago, it was expected that this dental products manufacturer would post earnings of $0.45 per share when it actually produced earnings of $0.37, delivering a surprise of -17.78%.Over the las ...

Key Takeaways MDLN will post Q4 results on Feb. 25, marking its first report since going public in December.MDLN Prime Vendor model aims to deepen ties and boost branded product penetration.Consensus estimate calls for $7.52B in revenue and earnings of 24 cents per share.Medline Inc. (MDLN) is slated to report fourth-quarter 2025 results on Feb. 25, before market open. This will be MDLN’s first quarterly results as a publicly traded company after making its market debut on Dec. 17, 2025, marking an importan ...

Key Takeaways BTSG is set to report Q4 2025 results on Feb. 27, with revenues seen at $3.35B and EPS at 34 cents.Pharmacy Solutions likely drove growth on specialty scripts, generics and new drug launches.BTSG may post stronger margins, aided by mix gains, cost control and seasonal strength.BrightSpring Health Services, Inc. (BTSG) is scheduled to release fourth-quarter 2025 results on Feb. 27, before market open. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 11.1 ...

Core Viewpoint - The market anticipates West Pharmaceutical Services (WST) to report a year-over-year earnings increase driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Group 1: Earnings Expectations - The consensus estimate for quarterly earnings is $1.83 per share, reflecting a year-over-year change of +0.6% [3] - Expected revenues are projected at $794.26 million, which is a 6.1% increase from the same quarter last year [3] Group 2: Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - West Pharmaceutical's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.78%, suggesting a bearish sentiment among analysts [11] Group 3: Historical Performance - In the last reported quarter, West Pharmaceutical exceeded the expected earnings of $1.67 per share by delivering $1.96, resulting in a surprise of +17.37% [12] - The company has beaten consensus EPS estimates in all four of the last quarters [13] Group 4: Market Sentiment and Stock Movement - The stock may experience upward movement if the upcoming earnings report exceeds expectations, while a miss could lead to a decline [2] - Despite a potential earnings beat, other factors may influence stock performance, making it essential to consider broader market conditions [14][16]

分组1 - Cardinal Health reported quarterly earnings of $2.63 per share, exceeding the Zacks Consensus Estimate of $2.39 per share, and up from $1.93 per share a year ago, representing an earnings surprise of +9.86% [1] - The company achieved revenues of $65.63 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.90%, and an increase from $55.26 billion year-over-year [2] - Cardinal has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates two times during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.78 on revenues of $62.78 billion, and for the current fiscal year, it is $10.04 on revenues of $259.68 billion [7] - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

We recently compiled a list of the 12 Cheap Small-Cap Stocks to Invest In Before the Next Breakout.  STAAR Surgical Company tops our list for being one of the best small-cap stocks on our list. TheFly reported on January 16 that Morgan Stanley resumed coverage of STAA with an Underweight rating and a $13 price target following the termination of its merger agreement with Alcon (ALC). The firm described STAAR’s EVO ICL technology as “impressive” but noted it remains a niche product with a limited addressab ...

Core Viewpoint - Seaport Research initiated coverage of Birkenstock with a Neutral rating, indicating concerns over slowing Google search interest growth year-over-year and a significant decline in U.S. search interest for the Boston model during the holiday season [1] Group 1: Company Initiations - Seaport Research initiated coverage of Birkenstock (BIRK) with a Neutral rating and no price target, citing slowing search interest [1] - Freedom Capital initiated coverage of Unity (U) with a Buy rating and a price target of $52, highlighting promising early traction for Unity's Vector AI technology and a valuation multiple under half that of AppLovin [1] - Freedom Capital initiated coverage of Phinia (PHIN) with a Buy rating and a price target of $82, noting its role as a global supplier benefiting from recurring replacement demand and cyclical exposure to vehicle production [1] - Morgan Stanley resumed coverage of Staar Surgical (STAA) with an Underweight rating and a price target of $13, following the termination of its merger agreement with Alcon, expressing concerns over the niche market for EVO ICL technology [1] - B. Riley initiated coverage of Knife River (KNF) with a Buy rating and a price target of $92, suggesting the stock is mispriced after recent underperformance compared to peers [1]

Market Overview - Futures are trading higher, indicating a potential positive close to the week after a significant rally on Thursday, driven by a combination of factors including positive economic data and strong earnings reports from major banks [1] - The Dow Jones closed up 0.60% at 49,442, the S&P 500 rose 0.26% to 6,944, and the Nasdaq increased by 0.25% to 23,530, with the Russell 2000 leading the gains at 0.86% [1] Treasury Bonds - Treasury yields increased across the curve as sellers returned, influenced by positive inflation reports and labor market news, which led to speculation that interest rate cuts may be delayed until June [2] - The 30-year bond closed at 4.80%, while the 10-year note was at 4.17% [2] Oil and Gas - Oil prices fell sharply, with Brent Crude down 4.12% to $63.78 and West Texas Intermediate down 4.42% to $59.28, ending a five-day winning streak due to reduced military tensions and oversupply concerns [3] - Natural gas saw a slight increase, closing at $3.14, up 0.74% [3] Gold and Silver - Gold prices experienced a minor decline of 0.24%, closing at $4,615, attributed to profit-taking and reduced geopolitical tensions [4] - Silver also fell by 0.84% to $92.29, with traders noting it may not be included in the critical minerals tariff list for now [4] Cryptocurrency - The cryptocurrency market faced a downturn, primarily due to the postponement of a key US Senate crypto bill, with Bitcoin dropping below $96,000 during trading [5] - Bitcoin was trading at $95,357 and Ethereum at $3,304 at 8 AM EST [5] Analyst Upgrades - Garmin Ltd. upgraded to Equal Weight from Underweight with a target price increase to $217 from $208 [12] - Honeywell International Inc. upgraded to Overweight from Neutral, target price raised to $255 from $218 [12] - PepsiCo Inc. raised to Outperform from Neutral with a target price of $179 [12] - Rocket Lab Corp. upgraded to Overweight from Equal Weight, target price increased to $105 from $67 [12] - Seagate Technology Holdings plc raised to Neutral from Negative, target price increased to $280 from $150 [12] Analyst Downgrades - ConocoPhillips downgraded to Underperform from Neutral with a target price of $102 [12] - Devon Energy Corp. downgraded to Sector Perform from Outperform, target price set at $41 [12] - HP Inc. cut to Underweight from Equal Weight, target price reduced to $18 from $24 [12] - Kraft Heinz Co. downgraded to Underweight from Equal Weight, target price trimmed to $24 from $27 [12] - MGM Resorts International cut to Underweight from Equal Weight, target price lowered to $33 from $40 [12] Analyst Initiations - Martin Marietta Materials Inc. initiated with a Neutral rating and a target price of $700 [12] - Staar Surgical Co. resumed coverage with an Underweight rating and a target price of $13 [12] - TFS Financial Corp. assumed coverage with a Neutral rating and a target price of $15 [12] - Unity Software Inc. started with a Buy rating and a target price of $52 [12] - Vulcan Materials Inc. initiated with a Buy rating and a target price of $345 [12]

Group 1 - Broadwood Partners has acquired a 31% stake in STAAR Surgical and initiated a proxy battle, which resulted in STAAR shareholders rejecting Alcon's $1.6 billion takeover offer [3][8] - Following the rejection of Alcon's offer, STAAR and Broadwood reached a cooperation agreement that includes board changes, with STAAR agreeing to accept the resignations of CEO Stephen Farrell and chair Elizabeth Yeu [4][5][8] - The cooperation agreement allows Broadwood to potentially receive up to $6 million from STAAR and includes a commitment from both parties not to disparage each other, which aims to reduce distractions for the company [6][7] Group 2 - As part of the board reshaping, STAAR will increase its board size and support the nominations of three new directors, including Broadwood's president and executive vice president [5][8] - The cooperation agreement has postponed any special meeting to remove STAAR directors until at least June 18, 2024, which is the first anniversary of STAAR's 2025 annual meeting [4][6] - The focus will now shift to finding a new CEO and developing a strategy for STAAR as an independent entity [7]

Insider Purchases Overview - A beneficial owner is increasing their stake in W.R. Berkley Corp. (NYSE: WRB), while a director has made significant purchases in Navan Inc. (NASDAQ: NAVN) [1] - Insider buying is often viewed as a positive signal for potential investors, especially during uncertain market conditions [2] W.R. Berkley Corp. - Mitsui Sumitomo has agreed to acquire 15% of W.R. Berkley's shares, increasing its stake to over 51.9 million shares, or more than 13% [5] - The stock has seen a year-over-year increase of 22.1%, outperforming the S&P 500, despite recent volatility [6] - Analysts are cautious, with only four out of 18 recommending a buy, and the mean price target is $72.50, which is 5.6% higher than the current price [6] Navan Inc. - Navan, a cloud-based technology platform, saw its share price decline after disappointing quarterly results but has since recovered [9] - The stock is currently trading 12.1% below its IPO price, yet remains within the director's purchase price range [9] - All 12 analysts covering Navan recommend buying shares, with a consensus price target of $25.08, indicating a potential upside of 41.1% [10] Other Notable Insider Purchases - Staar Surgical Co. (NASDAQ: STAA): A 10% owner purchased over 406,650 shares at prices ranging from $20.92 to $22.58, totaling over $8.8 million [15] - Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL): A 10% owner bought almost 6.5 million shares at $1.20, costing nearly $7.8 million [15] - Par Technology Corp. (NYSE: PAR): A 10% owner acquired over 196,000 shares at prices between $34.56 and $36.60, totaling over $7.1 million [15] - Hycroft Mining Holding Corp. (NASDAQ: HYMC): A 10% owner purchased 125,000 shares at prices from $26.08 to $27.05, costing almost $3.3 million [15] - Flywire Corp. (NASDAQ: FLYW): A 10% owner bought over 226,100 shares at prices between $4.15 and $4.24, amounting to about $3.2 million [15]